Intercept ‘lowers the bar’ on its pivotal PhIII OCA study for NASH
Intercept CEO Mark Pruzanski has redrawn the rules on their pivotal Phase III study of obeticholic acid (OCA).
After talks with the FDA, Pruzanski said …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
